Aeglea Bio Therapeutics Inc.

12/05/2021 | Press release | Distributed by Public on 12/05/2021 17:06

Aeglea BioTherapeutics to Host Conference Call to Report Phase 3 Topline Results of Pegzilarginase in Patients with Arginase 1 Deficiency